Loading clinical trials...

COMPLETEDNA

High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m)

Comparative Study of Pulmonary Artery Pressure (PAP) Assessed by Echocardiography in Patients With High Altitude Pulmonary Hypertension (HAPH) Permanently Residing Above 2500 Meters When Assessed Near Resident High Altitude (HA) at 3200 m vs. at Low Altitude (LA) at 760 m

NCT06489704•University of Zurich

View on ClinicalTrials.gov

Summary

To study the effect of relocation from 3200 m (Aksay) to 760 m (Bishkek) in patients with high altitude pulmonary hypertension (HAPH) who permanently live \>2500 m on pulmonary artery pressure (PAP)

Detailed Description

This research in highlanders with HAPH diagnosed by echocardiography and defined by a RV/RA \>30 mmHg who permanently live at HA \>2500 m will have pulmonary arterial pressure (PAP) assessed by echocardiography near their living altitude in Aksay at 3200 m and at 760 m in Bishkek the day after the first and the seventh night after relocation.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Permanently living \>2500 m
•HAPH diagnosed with a minimum RV/RA of 30 mmHg assessed by echocardiography at an altitude of 3200 m
•Written informed consent

Exclusion Criteria

•Highlanders who cannot follow the study investigations,
•Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, heavy smoking \>20 cigarettes/day or \>20 pack-years.
•Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months
•Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)

Locations (1)

Aksay Medical Center

Aksay Plateau, Naryn, Kyrgyzstan, Kyrgyzstan, Kyrgyzstan

Key Dates

Start Date

July 2, 2024

Primary Completion Date

September 27, 2024

Completion Date

September 27, 2024

Last Updated

January 21, 2026

Enrollment

ACTUAL participants

Conditions

High Altitude Pulmonary Hypertension

Interventions

Echocardiography

OTHER

HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.

NCT06489730

High Altitude Pulmonary HypertensionSleep Apnea

View study

COMPLETED

Cerebral Tissue Oxygenation in Highlanders/Lowlanders

NCT03172429

High Altitude Pulmonary Hypertension

View study

COMPLETEDPHASE1

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 21, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m)

Inclusion Criteria

Exclusion Criteria

HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.

Cerebral Tissue Oxygenation in Highlanders/Lowlanders

The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers